Table 1.
Patient baseline characteristics, by treatment.
| Variable | Ezetimibe/placebo (n = 25) |
Placebo/ezetimibe (n = 23) |
Overall (n = 48) |
|---|---|---|---|
| Male sex | 19 (76) | 18 (78) | 37 (77) |
| Ethnicity | |||
| Black, non-Hispanic | 12 (48) | 11 (48) | 23 (48) |
| White, non-Hispanic | 12 (48) | 10 (43) | 22 (46) |
| Other | 1 (4) | 2 (9) | 3 (6) |
| Age, mean years ± SD | 47 ± 5.8 | 46 ± 7.3 | 46 ± 6.5 |
| Cholesterol level, mean mg/dL ± SD | |||
| Direct LDL | 131 ± 38.2 | 125 ± 29.7 | 128 ± 34.2 |
| HDL | 51 ± 15.3 | 47 ± 8.0 | 49 ± 12.4 |
| Triglycerides after fasting | 166 ± 80.0 | 163 ± 75.7 | 165 ± 77.2 |
| Body mass index,a mean ± SD | 32 ± 23.4 | 31 ± 8.1 | 32 ± 17.5 |
| CD4 count, mean cells/uL | 592 ± 230 | 596 ± 311 | 594 ± 269 |
| HIV RNA level <400 copies/mL | 23 (92) | 20 (87) | 43 (90) |
NOTE. Data are no. (%) of patients, unless otherwise indicated. Ezetimibe/placebo, the group that received ezetimibe in the first 6-week period and placebo in the second 6-week period; placebo/ezetimibe, the group receiving therapy in the reverse order.
a
Calculated as the weight in kilograms divided by square of the height in meters.